Mobilization and collection of peripheral blood progenitor cells PBPC) from AIDS patients (Meeting abstract).

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Mobilization and collection of peripheral blood progenitor cells PBPC) from AIDS patients (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 16:A157 1997. Unique Identifier : AIDSLINE MED/97622148
Law P; Schwarz L; Looney D; Gervaix A; Young D; Wong-Staal F; Ho AD; Lane TA; University of California, San Diego, CA

Abstract: Hematopoietic stem cells are ideal vehicles for gene therapy because of their capacities of self-renewal and differentiation into all lineages of mature blood cells. In this study, we evaluated the possibility of mobilizing PBPC in AIDS patients by administration of G-CSF (10 mg/kg/dx6d). Leukapheresis product LP) of PBPC was collected by processing 10 liters of blood on day 7. Currently, 6 patients have completed the protocol. The growth factor injection regimen was well tolerated by study subjects. Major side effects included bone pain, head-ache and flu-like symptoms, and were controlled by non-steroidal anti-inflammatory agents. No significant increase in viremia HIV-1 copy number) was detected during G-CSF injection, but transient elevations in the CD4+ cells and CD8+ cells was observed. Both values returned to baseline level 48 hr after the last growth factor injection. CD34+ cells in PB and LP were compared to normal individuals injected with G-CSF or GM-CSF + G-CSF (GM/G) (5 /mg/kg/d each) as shown in a table. During mobilization, PB WBC increased from 5.8+/-1.3 to 40.8+/-6.0x10(3)/ml (7.1-fold increase) and CD34+ cells, 16.4 to 74.0 (7.6-fold). In the LP, 2 x 10(6) CD34+ cells/kg can be procured for 2 out of 6 AIDS patients, compared to 4/7 G-CSF mobilized, and 2/6 GM/G mobilized normal subjects. Primitive subset of CD38' cells was 1.2% of all CD34+ cells in LP, similar to the G-CSF subjects, but lower than that from GM/G subjects. We concluded that, in AIDS patients, (1) injecting G-CSF is safe and well tolerated; (2) mobilization of PBPC can be achieved; and (3) sufficient quantities of PBPC can be collected for subsequent gene therapy manipulations. (C) American Society of Clinical Oncology 1997

Keywords: *Acquired Immunodeficiency Syndrome/THERAPY *Granulocyte Colony-Stimulating Factor/ADMINISTRATION & DOSAGE *Hematopoietic Stem Cells/IMMUNOLOGY
971230
M97C1602

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .